MorphoSys AG (MOR.SG)
| Previous close | 66.05 |
| Open | 65.90 |
| Bid | 66.55 x 27700 |
| Ask | 66.60 x 21000 |
| Day's range | 65.90 - 66.90 |
| 52-week range | 14.90 - 67.95 |
| Volume | |
| Avg. volume | 5,790 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
MorphoSys AG Reports First Quarter 2024 Financial Results
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
- Business Wire
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
PLANEGG/MUNICH, Germany, April 11, 2024--The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total e
- Business Wire
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
